We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Stock Sinks As Market Gains: Here's Why
Read MoreHide Full Article
Medtronic (MDT - Free Report) ended the recent trading session at $95.34, demonstrating a -1.24% change from the preceding day's closing price. This change lagged the S&P 500's 0.4% gain on the day. Elsewhere, the Dow saw a downswing of 0.04%, while the tech-heavy Nasdaq appreciated by 0.66%.
Prior to today's trading, shares of the medical device company had gained 2.49% outpaced the Medical sector's gain of 1.8% and the S&P 500's gain of 1.02%.
Investors will be eagerly watching for the performance of Medtronic in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 18, 2025. The company is predicted to post an EPS of $1.31, indicating a 3.97% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $8.86 billion, indicating a 5.44% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $5.62 per share and revenue of $35.83 billion, which would represent changes of +2.37% and +6.82%, respectively, from the prior year.
Any recent changes to analyst estimates for Medtronic should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. As of now, Medtronic holds a Zacks Rank of #3 (Hold).
In terms of valuation, Medtronic is presently being traded at a Forward P/E ratio of 17.19. This denotes a discount relative to the industry average Forward P/E of 17.45.
Also, we should mention that MDT has a PEG ratio of 2.54. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MDT's industry had an average PEG ratio of 2.25 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 91, positioning it in the top 37% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medtronic (MDT) Stock Sinks As Market Gains: Here's Why
Medtronic (MDT - Free Report) ended the recent trading session at $95.34, demonstrating a -1.24% change from the preceding day's closing price. This change lagged the S&P 500's 0.4% gain on the day. Elsewhere, the Dow saw a downswing of 0.04%, while the tech-heavy Nasdaq appreciated by 0.66%.
Prior to today's trading, shares of the medical device company had gained 2.49% outpaced the Medical sector's gain of 1.8% and the S&P 500's gain of 1.02%.
Investors will be eagerly watching for the performance of Medtronic in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 18, 2025. The company is predicted to post an EPS of $1.31, indicating a 3.97% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $8.86 billion, indicating a 5.44% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $5.62 per share and revenue of $35.83 billion, which would represent changes of +2.37% and +6.82%, respectively, from the prior year.
Any recent changes to analyst estimates for Medtronic should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. As of now, Medtronic holds a Zacks Rank of #3 (Hold).
In terms of valuation, Medtronic is presently being traded at a Forward P/E ratio of 17.19. This denotes a discount relative to the industry average Forward P/E of 17.45.
Also, we should mention that MDT has a PEG ratio of 2.54. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MDT's industry had an average PEG ratio of 2.25 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 91, positioning it in the top 37% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.